Recently in June 2021, the Food and Drug Administration approved avapritinib (Ayvakit) for adult patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive systemic mastocytosis (AS
FDA approves avapritinib for advanced systemic mastocytosis. FDA. Published June 16, 2021. Accessed June 16, 2021.https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-avapritinib-advanced-systemic-mastocytosis?utm_medium=email&utm_source=govdelivery...
Avapritinib已于2020年1月获美国FDA未附加条件的完全(full approval)批准该药上市,是目前首个且唯一上市的GIST精准靶向药物。4月23日,基石药业宣布,国家药品监督管理局(NMPA)已受理avapritinib用于治疗携带血小板衍生生长因子受体α(PDGFRA)外显子18突变(包括PDGFRA D842V突变)的不可手术切除或转移性GIST成人患者...
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the FDA's approva...
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the European Commission (EC) has expanded the current indication for AYVAKYT® (avapritinib) to include monotherapy for the treatment of adult patients with ...
(avapritinib) in patients with advanced systemic mastocytosis (SM). Consistent with previously reported EXPLORER trial results, the registrational data for AYVAKIT showed profound reductions in mast cell burden, high ov...
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present detailed results from the registrational PIONEER trial of AYVAKIT® (avapritinib) in indolent systemic mastocytosis (SM) at the 2023 American Academy...
Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis PR Newswire CAMBRIDGE, Mass., Nov. 22, 2022 -- Company to present...